• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Kyverna Therapeutics Inc.

    11/12/24 7:23:31 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYTX alert in real time by email
    SC 13G 1 tm2427940d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
    RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO
    13d-2 (b)

    (Amendment No. )

     

     

    Kyverna Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    501976104

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 501976104 13G  

    1.

    Name of Reporting Persons

     

    Westlake BioPartners Fund I, L.P. (“Westlake Fund I”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x 

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    3,787,940 shares, except that Westlake BioPartners GP I, LLC (“Westlake GP I”), the general partner of Westlake BioPartners Fund I, L.P. (“Westlake Fund I”), may be deemed to have sole voting power, and Dr. Beth C. Seidenberg (“Seidenberg”) and Dr. Sean E. Harper (“Harper”), the managing directors of Westlake GP I, may be deemed to have shared power to vote these shares.

    6.

    Shared Voting Power

     

    See response to row 5

    7.

    Sole Dispositive Power

     

    3,787,940 shares, except that Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole dispositive power, and Seidenberg and Harper, the managing directors of Westlake GP I, may be deemed to have shared power to dispose of these shares.

    8.

    Shared Dispositive Power

     

    See response to row 7

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,787,940

    10.

    Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ¨

    11.

    Percent of Class Represented by Amount in Row 9

     

    8.8%

    12.

    Type of Reporting Person (See Instructions)

     

    PN

                            

     

     

     

     

    CUSIP No. 501976104 13G  

    1.

    Name of Reporting Persons

     

    Westlake BioPartners GP I, LLC (“Westlake GP I”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    3,787,940 shares, all of which are owned directly by Westlake Fund I. Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole voting power, and Seidenberg and Harper, the managing directors of Westlake GP I, may be deemed to have shared power to vote these shares.

    6.

    Shared Voting Power

     

    See response to row 5.

    7.

    Sole Dispositive Power

     

    3,787,940 shares, all of which are owned directly by Westlake Fund I. Westlake GP I, the general partner of Westlake Fund I, may be deemed to have sole dispositive power, and Seidenberg and Harper, the managing directors of Westlake GP I, may be deemed to have shared power to dispose of these shares.

    8.

    Shared Dispositive Power

     

    See response to row 7.

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,787,940

    10.

    Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ¨

    11.

    Percent of Class Represented by Amount in Row 9

     

    8.8%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

                             

     

     

     

     

    CUSIP No. 501976104 13G  

    1.

    Name of Reporting Persons

     

    Westlake BioPartners Opportunity Fund I, L.P. (“Westlake Opportunity Fund I”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    735,984 shares, except that Westlake BioPartners Opportunity GP I, LLC (“Westlake Opportunity GP I”), the general partner of Westlake BioPartners Opportunity Fund I, L.P. (“Westlake Opportunity Fund I”), may be deemed to have sole voting power, and Seidenberg and Harper, the managing directors of Westlake Opportunity GP I, may be deemed to have shared power to vote these shares.

    6.

    Shared Voting Power

     

    See response to row 5

    7.

    Sole Dispositive Power

     

    735,984 shares, except that Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole dispositive power, and Seidenberg and Harper, the managing directors of Westlake Opportunity GP I, may be deemed to have shared power to dispose of these shares.

    8.

    Shared Dispositive Power

     

    See response to row 7

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    735,984

    10.

    Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ¨

    11.

    Percent of Class Represented by Amount in Row 9

     

    1.7%

    12.

    Type of Reporting Person (See Instructions)

     

    PN

                         

     

     

     

     

    CUSIP No. 501976104 13G  

    1.

    Name of Reporting Persons

     

    Westlake BioPartners Opportunity GP I, LLC (“Westlake Opportunity GP I”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    735,984 shares, all of which are owned directly by Westlake Opportunity Fund I. Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole voting power, and Seidenberg and Harper, the managing directors of Westlake Opportunity GP I, may be deemed to have shared power to vote these shares.

    6.

    Shared Voting Power

     

    See response to row 5.

    7.

    Sole Dispositive Power

     

    735,984 shares, all of which are owned directly by Westlake Opportunity Fund I. Westlake Opportunity GP I, the general partner of Westlake Opportunity Fund I, may be deemed to have sole dispositive power, and Seidenberg and Harper, the managing directors of Westlake Opportunity GP I, may be deemed to have shared power to dispose of these shares.

    8.

    Shared Dispositive Power

     

    See response to row 7.

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    735,984

    10.

    Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ¨

    11.

    Percent of Class Represented by Amount in Row 9

     

    1.7%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

                   

     

     

     

     

    CUSIP No. 501976104 13G  

    1.

    Name of Reporting Persons

     

    Dr. Beth C. Seidenberg (“Seidenberg”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,523,924 shares, of which 3,787,940 shares are owned directly by Westlake Fund I and 735,984 shares are owned directly by Westlake Opportunity Fund I. Westlake GP I and Westlake Opportunity GP I, the general partners of Westlake Fund I and Westlake Opportunity Fund I, respectively, may be deemed to have sole voting power over such shares, and Seidenberg and Harper, the managing directors of Westlake GP I and Westlake Opportunity GP I, may be deemed to have shared power to vote these shares.

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,523,924 shares, of which 3,787,940 shares are owned directly by Westlake Fund I and 735,984 shares are owned directly by Westlake Opportunity Fund I. Westlake GP I and Westlake Opportunity GP I, the general partners of Westlake Fund I and Westlake Opportunity Fund I, respectively, may be deemed to have sole dispositive power over such shares, and Seidenberg and Harper, the managing directors of Westlake GP I and Westlake Opportunity GP I, may be deemed to have shared power to dispose of these shares.

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,523,924

    10.

    Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ¨

    11.

    Percent of Class Represented by Amount in Row 9

     

    10.5%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

      

                   

     

     

     

     

    CUSIP No. 501976104 13G  

    1.

    Name of Reporting Persons

     

    Dr. Sean E. Harper (“Harper”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨ (b) x

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    4,523,924 shares, of which 3,787,940 shares are owned directly by Westlake Fund I and 735,984 shares are owned directly by Westlake Opportunity Fund I. Westlake GP I and Westlake Opportunity GP I, the general partners of Westlake Fund I and Westlake Opportunity Fund I, respectively, may be deemed to have sole voting power over such shares, and Seidenberg and Harper, the managing directors of Westlake GP I and Westlake Opportunity GP I, may be deemed to have shared power to vote these shares.

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    4,523,924 shares, of which 3,787,940 shares are owned directly by Westlake Fund I and 735,984 shares are owned directly by Westlake Opportunity Fund I. Westlake GP I and Westlake Opportunity GP I, the general partners of Westlake Fund I and Westlake Opportunity Fund I, respectively, may be deemed to have sole dispositive power over such shares, and Seidenberg and Harper, the managing directors of Westlake GP I and Westlake Opportunity GP I, may be deemed to have shared power to dispose of these shares.

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,523,924

    10.

    Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ¨

    11.

    Percent of Class Represented by Amount in Row 9

     

    10.5%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

      

                      

     

     

     

     

    Introductory Note: This joint statement on Schedule 13G (this “Statement”) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.00001 per share (“Common Stock”), of Kyverna Therapeutics, Inc. (the “Issuer”).

     

    Item 1(a). Name of Issuer:

     

    Kyverna Therapeutics, Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    5980 Horton St., STE 550

    Emeryville, CA 94608

     

    Item 2(a). Name of Person Filing:

     

    This Statement is being filed by Westlake BioPartners Fund I, L.P. (“Westlake Fund I”), Westlake BioPartners GP I, LLC (“Westlake GP I”), Westlake BioPartners Opportunity Fund I, L.P. (“Westlake Opportunity Fund I”) and Westlake BioPartners Opportunity GP I, LLC (“Westlake Opportunity GP I” and together with Westlake Fund I, Westlake GP I and Westlake Opportunity Fund I, the “Reporting Entities”) and Dr. Beth C. Seidenberg (“Seidenberg”) and Dr. Sean E. Harper (“Harper”) (together, the “Reporting Individuals”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons.”

     

    Item 2(b) Address of Principal Business Office, or if None, Residence:

     

    The address of the principal business office of each Reporting Person is c/o Westlake BioPartners, LLC, 3075 Townsgate Road, Suite 140, Westlake Village, California 91361.

     

    Item 2(c). Citizenship:

     

    Each of Westlake GP I and Westlake Opportunity GP I is a limited liability company organized under the laws of the State of Delaware. Each of Westlake Fund I and Westlake Opportunity Fund I is a limited partnership organized under the laws of the State of Delaware. Each of the Reporting Individuals is a citizen of the United States of America.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, $0.00001 par value per share.

     

    Item 2(e). CUSIP Number:

     

    501976104

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

      (a) Amount beneficially owned:

     

    See Row 9 of the cover page for each Reporting Person.*

     

     

     

     

      (b) Percent of class:

     

    See Row 11 of the cover page for each Reporting Person.*

     

      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote

     

    See Row 5 of the cover page for each Reporting Person.*

     

      (ii) Shared power to vote or to direct the vote

     

    See Row 6 of the cover page for each Reporting Person.*

     

      (iii) Sole power to dispose or to direct the disposition of

     

    See Row 7 of the cover page for each Reporting Person.*

     

      (iv) Shared power to dispose or to direct the disposition of

     

    See Row 8 of the cover page for each Reporting Person.*

     

    * Except to the extent of a Reporting Person’s pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Under certain circumstances set forth in the limited partnership agreement of each of Westlake Fund I and Westlake Opportunity Fund I and the limited liability company agreement of each of Westlake GP I and Westlake Opportunity GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of the Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    Not Applicable

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 8, 2024

     

    Westlake BioPartners Fund I, L.P.  
         
    By: Westlake BioPartners GP I, LLC  
    Its: General Partner  
         
    By: /s/ Jennifer L. Kercher  
      Jennifer L. Kercher  
      Attorney-in-Fact*  
       
    Westlake BioPartners GP I, LLC  
         
    By: /s/ Jennifer L. Kercher  
      Jennifer L. Kercher  
      Attorney-in-Fact*  
       
    Westlake BioPartners Opportunity Fund I, L.P.  
       
    By: Westlake BioPartners Opportunity GP I, LLC  
    Its: General Partner  
         
    By: /s/ Jennifer L. Kercher  
      Jennifer L. Kercher  
      Attorney-in-Fact*  
       
    Westlake BioPartners Opportunity GP I, LLC  
         
    By: /s/ Jennifer L. Kercher  
      Jennifer L. Kercher  
      Attorney-in-Fact*  
       
    Dr. Beth C. Seidenberg  
         
    By: /s/ Jennifer L. Kercher  
      Jennifer L. Kercher  
      Attorney-in-Fact*  
       
    Dr. Sean E. Harper  
         
    By: /s/ Jennifer L. Kercher  
      Jennifer L. Kercher  
      Attorney-in-Fact*  

     

    * This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are included herein as exhibits to this Schedule 13G.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit   Description 
         
    1   Joint Filing Agreement
    2   Power of Attorney – Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC
    3   Power of Attorney – Westlake BioPartners Opportunity Fund I, L.P. and Westlake BioPartners Opportunity GP I, LLC

     

     

     

    Get the next $KYTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KYTX

    DatePrice TargetRatingAnalyst
    10/10/2024$13.00Buy
    UBS
    10/9/2024$16.00Buy
    Rodman & Renshaw
    7/3/2024$8.00Neutral
    H.C. Wainwright
    3/4/2024$40.00Overweight
    Morgan Stanley
    3/4/2024$39.00Overweight
    JP Morgan
    3/4/2024$44.00Overweight
    Wells Fargo
    3/4/2024$48.00Outperform
    Leerink Partners
    More analyst ratings

    $KYTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kyverna Therapeutics Inc.

      10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)

      5/13/25 4:08:40 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)

      5/13/25 4:03:44 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Kyverna Therapeutics Inc.

      EFFECT - Kyverna Therapeutics, Inc. (0001994702) (Filer)

      4/16/25 12:15:18 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

      Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of growth EMERYVILLE, Calif., Jan. 21, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of Naji Gehchan, M.D., MBA, to Chief Medical and Development Officer, where he will lead the Company's research, clinical development, and medical affairs functions. Dr. Gehchan brings 20 years of U.S. and international experience across multiple

      1/21/25 4:05:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors

      SANTA CRUZ, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today the appointment of Abbas Kazimi and Mert Aktar to its Board of Directors. "We are honored to welcome Abbas and Mert to our Board of Directors," said Cameron Pye, Ph.D., CEO and Co-Founder of Unnatural Products. "Abbas has an exceptional history of advancing groundbreaking therapies and forging impactful partnerships, and Mert's vast experience in leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms will be instrumental as we a

      1/8/25 8:00:00 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

      Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations.  "I'm pleased to welcome three industry leaders to our Kyverna team," sai

      12/13/24 4:05:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Financials

    Live finance-specific insights

    See more
    • Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

      Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting

      4/11/24 5:01:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Kyverna Therapeutics with a new price target

      UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00

      10/10/24 7:37:04 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Kyverna Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $16.00

      10/9/24 7:50:11 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Kyverna Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Kyverna Therapeutics with a rating of Neutral and set a new price target of $8.00

      7/3/24 7:31:52 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026  Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA); Phase 2 MG data anticipated in 2H 2025 Company to host KOL event in Q3 2025, spotlighting its accelerating neuroinflammation franchise  Strong financial position; cash runway into 2027 supports first BLA filing, MG Phase 3 trial and pre-launch activities  EMERYVILLE, Calif., May 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc.

      5/13/25 4:02:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Application (BLA) filing targeted for 2026   Clinical data in myasthenia gravis and lupus nephritis expected in 2H 2025   Strong balance sheet extends cash runway into 2027 through key clinical and regulatory catalysts EMERYVILLE, Calif., March 27, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company fo

      3/27/25 4:02:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

      EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on th

      3/3/25 4:05:00 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Biddle Warner Weston

      4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

      4/15/25 5:42:51 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Jones Ryan Alexander was granted 12,000 shares, increasing direct ownership by 27% to 55,950 units (SEC Form 4)

      4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

      4/15/25 5:42:36 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Technology Officer Walker Karen Marie was granted 13,000 shares, increasing direct ownership by 135% to 22,636 units (SEC Form 4)

      4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

      4/15/25 5:40:15 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Kyverna Therapeutics Inc.

      SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

      11/12/24 7:23:31 AM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Kyverna Therapeutics Inc.

      SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)

      10/10/24 12:36:27 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Kyverna Therapeutics Inc.

      SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)

      5/3/24 5:57:02 PM ET
      $KYTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care